viernes, 13 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 11, 2025

Costco (COST) Q1 2026 Earnings Call Transcript

View original at nasdaq.com
“Net Income -- $2 billion or $4.50 per diluted share, compared to $1.8 billion or $4.04 per diluted share.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Excluding tax benefits, net income and EPS grew 13.6% year-over-year in Q1 2026

    80% confidence
  • Personalization system launched in Q1 showed positive sales lift

    80% confidence
  • Q1 was the first quarter where healthcare costs grew at faster pace than sales, creating SG&A headwinds

    80% confidence
  • Extended operating hours for executive members generated estimated ~1% sales lift

    80% confidence
  • Long-term geographic target is approximately 50% US and 50% international across Canada, Mexico, Europe, Asia, and Australia

    80% confidence
  • AI pharmacy inventory system improved in-stock levels to >98% with mid-teens script fill growth

    80% confidence
  • Renewal rate may still see a slight decline over next few quarters due to digitally-signed members with lower renewal rates

    80% confidence
  • Kirkland Signature is growing faster than overall sales with 15-20% value proposition vs national brands

    80% confidence
  • Executive membership upgrades saw a 'nice uptick' from extended hours and Instacart benefits

    80% confidence
  • FY2025 warehouse openings are achieving $192M annualized productivity per warehouse vs $150M for FY2023 openings

    80% confidence
  • Warehouse relocations typically generate 20-60% sales uplift

    80% confidence
  • Targeted communications to expiring digitally-signed members showing early success in improving renewal rates

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com